Genetically engineered fixed K562 cells: Potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells

Cytotherapy

Volumn 16, Issue 1, 2014, Pages 135-146

  Tanimoto, Kazushi ^a   Muranski, Pawel ^a   Miner, Samantha ^a   Fujiwara, Hiroshi ^b   Kajigaya, Sachiko ^a   Keyvanfar, Keyvan ^a   Hensel, Nancy ^a   Barrett, A John ^a   Melenhorst, J Joseph ^a,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Artificial APC; Cytomegalovirus; Cytotoxic T cell; Fixation

Indexed keywords

HLA A ANTIGEN; OKT 3; STAPHYLOCOCCUS ENTEROTOXIN B; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN K 562; CONTROLLED STUDY; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE EVASION; MIXED LYMPHOCYTE REACTION; NONHUMAN; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; WILD TYPE;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS;

ARTIFICIAL APC; CYTOMEGALOVIRUS; CYTOTOXIC T CELL; FIXATION;

ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; GENETIC ENGINEERING; HLA ANTIGENS; HUMANS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84891029261     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.08.008     Document Type: Article

References (41)

1. Barrett A.J., Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 2010, 161:223-232.
2. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012, 9:510-519.
3. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
4. Takamizawa M., Rivas A., Fagnoni F., Benike C., Kosek J., Hyakawa H., et al. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. JImmunol 1997, 158:2134-2142.
5. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002, 2:227-238.
6. Shuford W.W., Klussman K., Tritchler D.D., Loo D.T., Chalupny J., Siadak A.W., et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. JExp Med 1997, 186:47-55.
7. Bukczynski J., Wen T., Ellefsen K., Gauldie J., Watts T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004, 101:1291-1296.
8. Zhang H., Snyder K.M., Suhoski M.M., Maus M.V., Kapoor V., June C.H., et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. JImmunol 2007, 179:4910-4918.
9. Wolfl M., Kuball J., Ho W.Y., Nguyen H., Manley T.J., Bleakley M., et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210.
10. Comoli P., Basso S., Azzi A., Moretta A., De Santis R., Del Galdo F., et al. Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. JAm Soc Nephrol 2003, 14:3197-3204.
11. Li J., Melenhorst J., Hensel N., Rezvani K., Sconocchia G., Kilical Y., et al. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. JGen Virol 2006, 87:2951-2960.
12. Nair S., Archer G.E., Tedder T.F. Isolation and generation of human dendritic cells. Curr Protoc Immunol 2012, Chapter 7:Unit7.32.
13. Dupont J., Latouche J.B., Ma C., Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005, 65:5417-5427.
14. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002, 20:143-148.
15. Hirano N., Butler M.O., Xia Z., Berezovskaya A., Murray A.P., Ansen S., et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006, 12:2967-2975.
16. Ye Q., Loisiou M., Levine B.L., Suhoski M.M., Riley J.L., June C.H., et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. JTransl Med 2011, 9:131.
17. Melenhorst J.J., Solomon S.R., Shenoy A., Hensel N.F., McCoy J.P., Keyvanfar K., et al. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. JImmunother 2006, 29:436-443. discussion 365-6.
18. Yang S., Rosenberg S.A., Morgan R.A. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. JImmunother 2008, 31:830-839.
19. Yang S., Cohen C.J., Peng P.D., Zhao Y., Cassard L., Yu Z., et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 2008, 15:1411-1423.
20. Sloand E.M., Melenhorst J.J., Tucker Z.C., Pfannes L., Brenchley J.M., Yong A., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
21. Scheinberg P., Melenhorst J.J., Brenchley J.M., Hill B.J., Hensel N.F., Chattopadhyay P.K., et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype ofCMV-specific T cells in the donor. Blood 2009, 114:5071-5080.
22. Melenhorst J.J., Scheinberg P., Lu J., Ambrozak D.R., Sosa E., Zhao L., et al. Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture. Cytotherapy 2008, 10:152-164.
23. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. JExp Med 2007, 204:1405-1416.
24. Butler M.O., Lee J.S., Ansen S., Neuberg D., Hodi F.S., Murray A.P., et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007, 13:1857-1867.
25. Lin G.H., Sedgmen B.J., Moraes T.J., Snell L.M., Topham D.J., Watts T.H. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. JImmunol 2009, 182:934-947.
26. Sluijter B.J., van den Hout M.F., Stam A.G., Lougheed S.M., Suhoski M.M., van den Eertwegh A.J., et al. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clin Immunol 2010, 137:221-233.
27. Tiercy J.M., Nicoloso G., Passweg J., Schanz U., Seger R., Chalandon Y., et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant 2007, 40:515-522.
28. Pedron B., Guerin-El Khourouj V., Dalle J.H., Ouachee-Chardin M., Yakouben K., Corroyez F., et al. Contribution of HLA-A/B/C/DRB1/DQB1 common haplotypes to donor search outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1612-1618.
29. Tiercy J.M. Analysis of 250 HLA-B44 genotypes in European Caucasoids: high diversity and preferential ABCDRB1 associations in B*4402, B*4403, and B*4405 haplotypes. Tissue Antigens 2005, 65:429-436.
30. O'Connell R.M., Balazs A.B., Rao D.S., Kivork C., Yang L., Baltimore D. Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations. PLoS One 2010, 5. e12009.
31. Kerkar S.P., Muranski P., Kaiser A., Boni A., Sanchez-Perez L., Yu Z., et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010, 70:6725-6734.
32. Steenblock E.R., Fadel T., Labowsky M., Pober J.S., Fahmy T.M. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. JBiol Chem 2011, 286:34883-34892.
33. Hsu C., Hughes M.S., Zheng Z., Bray R.B., Rosenberg S.A., Morgan R.A. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. JImmunol 2005, 175:7226-7234.
34. Lozzio B.B., Lozzio C.B. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res 1979, 3:363-370.
35. Greiner J., Ringhoffer M., Taniguchi M., Li L., Schmitt A., Shiku H., et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004, 108:704-711.
36. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997, 89:1405-1412.
37. Yan M., Himoudi N., Basu B.P., Wallace R., Poon E., Adams S., et al. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Cancer Immunol Immunother 2011, 60:1243-1255.
38. Smith B.D., Kasamon Y.L., Kowalski J., Gocke C., Murphy K., Miller C.B., et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010, 16:338-347.
39. Brusic A., Hainz U., Wadleigh M., Neuberg D., Su M., Canning C.M., et al. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology 2012, 1:1095-1103.
40. Amanna I.J., Raue H.P., Slifka M.K. Development of a new hydrogen peroxide-based vaccine platform. Nat Med 2012, 18:974-979.
41. Hammer M.H., Brestrich G., Mittenzweig A., Roemhild A., Zwinger S., Subklewe M., et al. Generation of EBV-specific Tcells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety. JImmunother 2007, 30:817-824.